The ex vivo analysis of patient tissues revealed that BM HCC cases with high m6A modifications of ANLN mRNA, highlighting the potential therapeutic value of targeting the m6A modification in ANLN in HCC. This evidence concerns the gene ANLN and hepatocellular carcinoma.